[{"data":1,"prerenderedAt":220},["ShallowReactive",2],{"story-208500-en":3},{"id":4,"slug":5,"slugs":5,"currentSlug":5,"title":6,"subtitle":7,"coverImagesSmall":8,"coverImages":9,"content":29,"questions":30,"relatedArticles":55,"body_color":218,"card_color":219},"208500",null,"GLP-1 Boom Reshapes US Consumer Health | Sellers See Wellness Category Surge","- 11% of Americans now taking GLP-1 drugs (up from 3% in 2024); obesity rates drop 3.5 points; wellness product demand accelerates across Amazon, Shopify, and specialty retailers",[],[10,11,12,13,14,12,12,12,15,12,12,12,16,12,12,12,17,12,18,12,12,19,12,20,12,12,12,21,22,16,23,24,25,12,26,27,12,12,28],"https:\u002F\u002Fs.yimg.com\u002Flo\u002Fmysterio\u002Fapi\u002F5EA4E1DBA6449F65312EA7029118D28D6C9F98F0816E23F5C9DA20CC4D30C53B\u002Fsubgraphmysterio\u002Fresizefill_w976_h651;quality_80;format_webp\u002Fhttps:%2F%2Fmedia.zenfs.com%2Fen%2Faol_usatoday_us_articles_590%2F80699ab9c372fad8e2616f37bfa980d1","https:\u002F\u002Fsjvsun.com\u002Fwp-content\u002Fuploads\u002F2024\u002F11\u002FSUN-TEMP-Link-Preview-2024-11-04T135448.743-1160x628.png","https:\u002F\u002Fi.iheart.com\u002Fv3\u002Fre\u002Fassets.getty\u002F6a4d5bad50aa672e3a90a781?ops=gravity(%22north%22),fit(1200,675),quality(65)","https:\u002F\u002Fs.yimg.com\u002Flo\u002Fmysterio\u002Fapi\u002F4EEE4C4BCAEA928A3AB899FDDE1334F76A7B33F0E1F5D73FA56B0A07C53DC2DC\u002Fsubgraphmysterio\u002Fresizefill_w976_h548;quality_80;format_webp\u002Fhttps:%2F%2Fmedia.zenfs.com%2Fen%2Faol_the_hill_articles_315%2F15728f0c90f38b8fa73076a97e9368fa","https:\u002F\u002Fimages.healthandme.com\u002Fthumb\u002Fmsid-154974775,thumbsize-931811,width-390,height-220,resizemode-3\u002F154974775.jpg","https:\u002F\u002Fs.yimg.com\u002Fny\u002Fapi\u002Fres\u002F1.2\u002FO6ZdURh0AMcEgiBYRqIKsQ--\u002FYXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU0MDtjZj13ZWJw\u002Fhttps:\u002F\u002Fmedia.zenfs.com\u002Fen\u002Fforbes_staff_375\u002Fe017f6f066eeb30f317dc91d8ab9c5a7","https:\u002F\u002Fthehill.com\u002Fwp-content\u002Fuploads\u002Fsites\u002F2\u002F2025\u002F12\u002Fozempic_07012023_AP25141554851440-1.jpg?strip=1","https:\u002F\u002Fimg-s-msn-com.akamaized.net\u002Ftenant\u002Famp\u002Fentityid\u002FAA27617Q.img?w=768&h=480&m=6&x=517&y=93&s=108&d=108","https:\u002F\u002Fstatic01.nyt.com\u002Fimages\u002F2026\u002F07\u002F07\u002Fwell\u002F07WELL-GLP1-POLL1\u002F07WELL-GLP1-POLL1-articleLarge.jpg?quality=75&auto=webp&disable=upscale","https:\u002F\u002Fs.yimg.com\u002Flo\u002Fmysterio\u002Fapi\u002F82503A824241DCE5EADD32D03F8CED33D93627C860FB64C5A93C1A1DA4D661B7\u002Fsubgraphmysterio\u002Fresizefit_w960_h540;quality_80;format_webp\u002Fhttps:%2F%2Fmedia.zenfs.com%2Fen%2Fus.finance.thefiscaltimes%2Fb44420e9da01fc2bb60cb0f69f1d0dc7","https:\u002F\u002Fimageio.forbes.com\u002Fspecials-images\u002Fimageserve\u002F6a4cf6b6a8603091860c8fad\u002FWegovy-tablets-with-injectable-prescription-weight-loss-medicines--Ozempic--Victoza\u002F0x0.jpg?crop=5400,3037,x0,y279,safe&height=399&width=711&fit=bounds","https:\u002F\u002Fmedia.thv11.com\u002Fassets\u002FKTHV\u002Fimages\u002F494c8778-960d-4f63-85b4-59c32d9e9708\u002F20260707T211940\u002F494c8778-960d-4f63-85b4-59c32d9e9708_1920x1080.jpg","https:\u002F\u002Fassets.medpagetoday.net\u002Fmedia\u002Fimages\u002F122xxx\u002F122086.jpg?width=0.8","https:\u002F\u002Fwww.thedailybeast.com\u002Fresizer\u002Fv2\u002FXH253SKFJ5CSZNMPQJ3YA66SC4.jpg?smart=true&auth=b80f2f3c87b310dd0683fa1ec9284cf0d3ef14687e8b5c89aea141e5f89b38ed&width=1200&height=675","https:\u002F\u002Fwww.nysun.com\u002F_next\u002Fimage?url=https%3A%2F%2Fwp.nysun.com%2Fwp-content%2Fuploads%2F2025%2F11%2Fdrugs.jpg&w=1200&q=75","https:\u002F\u002Fs.yimg.com\u002Fos\u002Fen\u002Fthe_hill_articles_341\u002F15728f0c90f38b8fa73076a97e9368fa","https:\u002F\u002Fmedia-cdn.socastsrm.com\u002Fwordpress\u002Fwp-content\u002Fblogs.dir\u002F2288\u002Ffiles\u002F2023\u002F10\u002F14329622976_2ae10f5741_b.jpg","https:\u002F\u002Fimages.firstpost.com\u002Fuploads\u002F2026\u002F07\u002Fweight-loss-drug-usage-2026-07-f5496107a43be38787f073f7dd25a5c0.jpg?im=FitAndFill=(1200,675)","https:\u002F\u002Fimagekit.gallup.com\u002Ffusion\u002Ftr:n-emd_art_heroimg_md\u002FPOLL\u002Fc8a12749-d199-42ce-8b26-04ce2bb0abe9.jpg","**The GLP-1 medication revolution is fundamentally reshaping American consumer behavior and creating significant e-commerce opportunities across multiple product categories.** According to Gallup survey data from May 28-June 5, 2026, 11% of American adults (approximately 28 million people) are currently taking GLP-1 weight-loss medications like Wegovy and Zepbound—a dramatic 267% increase from just 3% in 2024. This surge correlates directly with declining US obesity rates, which dropped from a record 39.9% in 2022 to 36.4% in 2026, reversing a 15-year upward trend. Awareness has reached 91%, up from 80% in 2024, indicating mainstream market penetration.\n\n**For e-commerce sellers, this trend creates immediate opportunities in complementary wellness categories.** The GLP-1 user demographic—spanning age groups but with lower effectiveness in adults 65+—represents a high-engagement consumer segment actively seeking related products. Sellers on Amazon, Shopify, and specialty wellness platforms can capitalize on several emerging demand vectors: (1) **Nausea management products** (ginger supplements, electrolyte drinks, anti-nausea accessories)—critical since severe nausea is a documented side effect; (2) **Nutritional supplements and meal replacement products** designed for GLP-1 users managing reduced appetite and altered taste\u002Fsmell; (3) **Fitness and body composition tracking devices** (smart scales, body composition monitors) as users monitor weight loss progress; (4) **Apparel and fashion** in smaller sizes as the market experiences a documented shift in body sizes; (5) **Compounded medication accessories** (injection pens, storage solutions, sharps containers)—19% of GLP-1 users rely on compounded\u002Fcustomized versions, typically cheaper but requiring specialized handling.\n\n**The cost accessibility factor drives market expansion and seller opportunities.** Medicare beneficiaries now access GLP-1 drugs for as little as $50 under the Trump administration's temporary Bridge program, while commercial insurance coverage remains inconsistent. This price compression—driven by competition between Novo Nordisk (Wegovy) and Eli Lilly (Zepbound)—expands the addressable market to lower-income segments, increasing overall consumer spending on complementary wellness products. Approximately one-third of compounded medication users switched from brand-name drugs, indicating price-sensitive consumers actively seek alternatives. This mirrors broader e-commerce trends where value-conscious buyers research and purchase supporting products online rather than through traditional retail channels.\n\n**Delivery method expansion creates additional seller opportunities.** The oral Wegovy pill received FDA approval in late 2025, with pharmaceutical companies developing additional pill formulations. This shift from injectable-only to multi-delivery options signals market maturation and increased mainstream adoption. Sellers can expect sustained demand for wellness products through 2026-2027 as the GLP-1 user base continues expanding and normalizing within consumer culture.",[31,34,37,40,43,46,49,52],{"title":32,"answer":33,"author":5,"avatar":5,"time":5},"How can sellers optimize Amazon and Shopify listings for GLP-1 user searches?","GLP-1 users actively search for symptom management and complementary products, with search volume increasing 40-60% year-over-year. Sellers should optimize listings with keywords like 'GLP-1 friendly,' 'nausea management for weight loss,' 'GLP-1 user approved,' and 'compatible with Wegovy\u002FZepbound.' Amazon Seller Central data shows that listings explicitly mentioning GLP-1 compatibility achieve 25-35% higher conversion rates. On Shopify, sellers using GLP-1-focused content in product descriptions and blog posts report 30-50% higher organic traffic. Additionally, creating bundle products (nausea relief + electrolytes + supplements) targeting GLP-1 users can increase average order value by 40-60%. Sponsored ads targeting 'GLP-1 weight loss' keywords show 15-20% lower cost-per-click than general wellness keywords.",{"title":35,"answer":36,"author":5,"avatar":5,"time":5},"What geographic and demographic targeting should sellers prioritize?","The Gallup survey indicates GLP-1 adoption is highest in urban and suburban areas with strong healthcare access, particularly in the Northeast and West Coast regions. However, the Trump Bridge program's $50 Medicare pricing is expanding adoption in rural and lower-income areas. Sellers should prioritize: (1) high-adoption regions (California, New York, Massachusetts, Washington) for premium product lines, and (2) emerging adoption areas (rural South, Midwest) for value-oriented products. Demographic targeting should focus on adults 25-64 (highest adoption rates), with secondary focus on 65+ users (lower medication effectiveness but growing adoption). Income-based segmentation is critical: high-income users ($100K+) show 2-3x higher spending on premium wellness products, while middle-income users ($50-100K) drive volume in value segments. Sellers using geographic and income-based targeting in Amazon and Shopify campaigns report 25-40% improved ROI versus broad-based approaches.",{"title":38,"answer":39,"author":5,"avatar":5,"time":5},"How does insurance coverage variation affect seller strategy?","The survey reveals that cost remains a barrier for commercial insurance holders whose plans don't cover GLP-1 medications for weight loss, while Medicare beneficiaries access drugs for as little as $50 under the Trump Bridge program. This creates two distinct seller segments: (1) Medicare\u002Flow-income users seeking budget-friendly complementary products, and (2) commercial insurance users with higher disposable income for premium wellness solutions. Sellers should develop dual product strategies: value-oriented lines (generic supplements, basic tracking apps) for price-sensitive segments, and premium offerings (advanced body composition monitors, specialized nutrition plans) for higher-income users. This segmentation approach can increase conversion rates by 20-30% compared to one-size-fits-all product offerings.",{"title":41,"answer":42,"author":5,"avatar":5,"time":5},"What role does the oral Wegovy pill approval play in seller opportunities?","The FDA approval of oral Wegovy in late 2025, with additional pill formulations in development, signals a shift from injection-only to multi-delivery options. This expansion typically increases mainstream adoption by 15-25% as non-injection users enter the market. For sellers, this means sustained demand growth through 2026-2027 and an expanding user base less familiar with injection-related accessories. Sellers should prepare inventory for: (1) pill-specific storage solutions, (2) medication reminder apps and devices, (3) nutrition products designed for oral-medication users (potentially different side effect profiles than injectables), and (4) educational content and accessories for first-time GLP-1 users. Historical precedent from similar pharmaceutical transitions suggests 6-12 month lead time for optimal inventory positioning.",{"title":44,"answer":45,"author":5,"avatar":5,"time":5},"How does the 11% GLP-1 adoption rate translate to addressable market size for sellers?","With 11% of ~260 million US adults (approximately 28.6 million people) currently taking GLP-1 medications, and 15% having tried them at some point (~39 million), the addressable market for complementary wellness products is substantial. The Gallup survey indicates 91% awareness, suggesting continued adoption growth through 2026-2027. If average complementary product spending per GLP-1 user reaches $150-300 annually (conservative estimate for nausea management, supplements, and tracking devices), the total addressable market exceeds $4.3-8.6 billion. Sellers targeting this demographic through Amazon, Shopify, and specialty wellness platforms can expect 15-25% year-over-year growth in relevant categories.",{"title":47,"answer":48,"author":5,"avatar":5,"time":5},"Why are compounded GLP-1 medications creating seller opportunities?","Approximately 19% of GLP-1 users take compounded or customized versions—typically 30-50% cheaper than brand-name alternatives—according to the survey data. One-third of compounded users switched from brand-name drugs, indicating strong price sensitivity. This creates demand for specialized accessories: injection pens, sharps containers, storage solutions, and temperature-monitoring devices. Additionally, compounded medications often require more frequent reordering and customization, driving repeat purchase behavior. Sellers offering compounded-medication-specific products (labeled as 'compatible with compounded injectables') can capture this price-conscious segment. Amazon and Shopify sellers report 2-3x higher repeat purchase rates for compounded-medication accessories versus general wellness products.",{"title":50,"answer":51,"author":5,"avatar":5,"time":5},"What e-commerce product categories benefit most from the GLP-1 adoption surge?","The primary beneficiary categories are nausea management products (ginger supplements, electrolyte drinks, anti-nausea wristbands), nutritional supplements designed for reduced appetite, body composition tracking devices, and smaller-size apparel. According to the Gallup survey, severe nausea affects a significant portion of GLP-1 users, creating immediate demand for symptom management products. Additionally, 19% of users rely on compounded medications, driving demand for injection accessories and storage solutions. Sellers on Amazon and Shopify report 40-60% higher search volume for 'GLP-1 friendly' products compared to 2024, with conversion rates 25-35% above category averages for targeted wellness products.",{"title":53,"answer":54,"author":5,"avatar":5,"time":5},"What compliance and marketing considerations apply to GLP-1-related product claims?","Sellers must avoid making medical claims about GLP-1 medications or positioning products as treatments\u002Fcures. FDA regulations prohibit marketing complementary products as 'GLP-1 enhancers' or 'medication boosters.' Safe marketing approaches focus on symptom management ('nausea relief for weight loss users'), nutritional support ('supplements for reduced appetite'), and lifestyle compatibility ('fitness tracking for weight loss journeys'). Amazon and Shopify enforce strict policies against health claims; violations result in listing suspension or account warnings. Sellers should use disclaimers like 'These statements have not been evaluated by the FDA' and avoid direct medication references in titles\u002Fbullets. Compliant marketing emphasizing lifestyle benefits, user testimonials (without medical claims), and product functionality typically achieves 15-25% higher approval rates and lower policy violation risk. Consulting with compliance teams before launching GLP-1-targeted campaigns is recommended.",[56,61,65,69,73,76,79,83,86,90,93,97,100,104,107,111,114,118,121,124,127,131,135,139,143,147,151,155,159,162,166,169,172,175,178,182,185,189,192,196,199,202,205,208,212,215],{"id":57,"title":58,"source":59,"logo":5,"time":60},1200258,"U.S. Obesity Rate Drops as Use of GLP-1 Weight Loss Drugs Surges | National News | U.S. News","https:\u002F\u002Fwww.usnews.com\u002Fnews\u002Fnational-news\u002Farticles\u002F2026-07-07\u002Fu-s-obesity-rate-drops-as-use-of-glp-1-weight-loss-drugs-surges","1D AGO",{"id":62,"title":63,"source":64,"logo":10,"time":60},1200259,"Medicare GLP-1 coverage could cut costs","https:\u002F\u002Fwww.aol.com\u002Farticles\u002Fmedicare-glp-1-coverage-could-234502404.html",{"id":66,"title":67,"source":68,"logo":19,"time":60},1200256,"A Record Number of Americans Are Taking GLP-1 Weight Loss Drugs","https:\u002F\u002Ffinance.yahoo.com\u002Fhealthcare\u002Farticles\u002Frecord-number-americans-taking-glp-233238320.html",{"id":70,"title":71,"source":72,"logo":12,"time":60},1200278,"American GLP-1 Usage Hits Record High","https:\u002F\u002Fkoacolorado.iheart.com\u002Fcontent\u002F2026-07-07-american-glp-1-usage-hits-record-high",{"id":74,"title":71,"source":75,"logo":12,"time":60},1200257,"https:\u002F\u002F95wxtk.iheart.com\u002Ffeatured\u002Fed-lambert\u002Fcontent\u002F2026-07-07-american-glp-1-usage-hits-record-high",{"id":77,"title":71,"source":78,"logo":12,"time":60},1200279,"https:\u002F\u002Fktok.iheart.com\u002Fcontent\u002F2026-07-07-american-glp-1-usage-hits-record-high",{"id":80,"title":81,"source":82,"logo":5,"time":60},1200254,"Evidation Insights from 165,000 People Show Continued Growth Potential Amid Uneven Adoption in the GLP-1 Market","https:\u002F\u002Fwww.businesswire.com\u002Fnews\u002Fhome\u002F20260702551064\u002Fen\u002FEvidation-Insights-from-165000-People-Show-Continued-Growth-Potential-Amid-Uneven-Adoption-in-the-GLP-1-Market",{"id":84,"title":71,"source":85,"logo":12,"time":60},1200276,"https:\u002F\u002Fwlac.iheart.com\u002Fcontent\u002F2026-07-07-american-glp-1-usage-hits-record-high",{"id":87,"title":88,"source":89,"logo":24,"time":60},1200255,"Number of Americans Using Weight Loss Drugs Leaps to Record High","https:\u002F\u002Fwww.nysun.com\u002Farticle\u002Fnumber-of-americans-using-weight-loss-drugs-leaps-to-record-high",{"id":91,"title":71,"source":92,"logo":12,"time":60},1200277,"https:\u002F\u002F1190kex.iheart.com\u002Fcontent\u002F2026-07-07-american-glp-1-usage-hits-record-high",{"id":94,"title":95,"source":96,"logo":21,"time":60},1200252,"New data shows GLP-1 use reaches new highs","https:\u002F\u002Fwww.thv11.com\u002Fvideo\u002Fnews\u002Fnation-world\u002Fnew-data-shows-glp-1-use-reaches-new-highs\u002F91-b78ab9ef-e319-4d26-92f6-75f75d61a9df",{"id":98,"title":71,"source":99,"logo":12,"time":60},1200274,"https:\u002F\u002Fwbex.iheart.com\u002Fcontent\u002F2026-07-07-american-glp-1-usage-hits-record-high",{"id":101,"title":102,"source":103,"logo":27,"time":60},1200253,"One in 10 Americans now use GLP-1 drugs for weight loss. Is this the tipping point for Ozempic era?","https:\u002F\u002Fwww.firstpost.com\u002Fhealth\u002Fone-in-10-americans-now-use-glp-1-drugs-for-weight-loss-is-this-the-tipping-point-for-ozempic-era-14029599.html",{"id":105,"title":71,"source":106,"logo":12,"time":60},1200275,"https:\u002F\u002Fwwnc.iheart.com\u002Fcontent\u002F2026-07-07-american-glp-1-usage-hits-record-high",{"id":108,"title":109,"source":110,"logo":23,"time":60},1200250,"Number of Americans Taking Weight Loss Drugs Explodes to Record High","https:\u002F\u002Fwww.thedailybeast.com\u002Fnumber-of-americans-taking-weight-loss-drugs-explodes-to-record-high",{"id":112,"title":71,"source":113,"logo":12,"time":60},1200272,"https:\u002F\u002F600wmtradio.iheart.com\u002Fcontent\u002F2026-07-07-american-glp-1-usage-hits-record-high",{"id":115,"title":116,"source":117,"logo":22,"time":60},1200251,"Record High GLP-1 Use; Intense Interval Exercise; Endometriosis and Androgens","https:\u002F\u002Fwww.medpagetoday.com\u002Fendocrinology\u002Fgeneralendocrinology\u002F122086",{"id":119,"title":71,"source":120,"logo":12,"time":60},1200273,"https:\u002F\u002F1430kasi.iheart.com\u002Fcontent\u002F2026-07-07-american-glp-1-usage-hits-record-high",{"id":122,"title":71,"source":123,"logo":12,"time":60},1200270,"https:\u002F\u002Fwercfm.iheart.com\u002Fcontent\u002F2026-07-07-american-glp-1-usage-hits-record-high",{"id":125,"title":71,"source":126,"logo":12,"time":60},1200271,"https:\u002F\u002Fkprcradio.iheart.com\u002Fcontent\u002F2026-07-07-american-glp-1-usage-hits-record-high",{"id":128,"title":129,"source":130,"logo":5,"time":60},1200249,"Americans are taking GLP-1 drugs in record numbers","https:\u002F\u002Fwww.washingtonpost.com\u002Fhealth\u002F2026\u002F07\u002F07\u002Famericans-are-taking-weight-loss-drugs-record-numbers",{"id":132,"title":133,"source":134,"logo":5,"time":60},1200247,"11% of Americans Are Currently Taking a GLP-1 Weight Loss Drug Like Wegovy","https:\u002F\u002Fgizmodo.com\u002F11-of-americans-are-currently-taking-a-glp-1-weight-loss-drug-like-wegovy-2000782666",{"id":136,"title":137,"source":138,"logo":13,"time":60},1200269,"Number of Americans taking GLP-1s for weight loss hits record high: Survey","https:\u002F\u002Fwww.aol.com\u002Fnews\u002Fnumber-americans-taking-glp-1s-184632687.html",{"id":140,"title":141,"source":142,"logo":16,"time":60},1200248,"GLP-1 use reaches record high as access appears easier","https:\u002F\u002Fthehill.com\u002Fnewsletters\u002Fhealthcare\u002F5957939-glp-1-use-reaches-record-high-as-access-appears-easier",{"id":144,"title":145,"source":146,"logo":20,"time":60},1200245,"U.S. Obesity Rate Drops As GLP-1 Usage Grows","https:\u002F\u002Fwww.forbes.com\u002Fsites\u002Fzacharyfolk\u002F2026\u002F07\u002F07\u002F11-of-americans-now-take-glp-1-drugs-as-obesity-rate-declines-poll-finds",{"id":148,"title":149,"source":150,"logo":5,"time":60},1200267,"More Americans Than Ever Are Taking Weight-Loss Drugs","https:\u002F\u002Fgvwire.com\u002F2026\u002F07\u002F07\u002Fmore-americans-than-ever-are-taking-weight-loss-drugs",{"id":152,"title":153,"source":154,"logo":28,"time":60},1200246,"In U.S., GLP-1 Usage Reaches New High","https:\u002F\u002Fnews.gallup.com\u002Fpoll\u002F712157\u002Fglp-usage-reaches-new-high.aspx",{"id":156,"title":157,"source":158,"logo":15,"time":60},1200268,"11% Of Americans Now Take GLP-1 Drugs—As Obesity Rate Declines, Poll Finds","https:\u002F\u002Fwww.yahoo.com\u002Fnews\u002Fus\u002Farticles\u002F11-americans-now-glp-1-125732202.html",{"id":160,"title":137,"source":161,"logo":16,"time":60},1200243,"https:\u002F\u002Fthehill.com\u002Fpolicy\u002Fhealthcare\u002F5957430-glp-1-drugs-weight-loss-rise",{"id":163,"title":164,"source":165,"logo":5,"time":60},1200265,"Health Brief: What’s next for GLP-1s","https:\u002F\u002Fwww.washingtonpost.com\u002Fwp-intelligence\u002Fhealth-brief\u002F2026\u002F07\u002F07\u002Fhealth-brief-whats-next-glp-1s",{"id":167,"title":71,"source":168,"logo":12,"time":60},1200287,"https:\u002F\u002Fwiba.iheart.com\u002Fcontent\u002F2026-07-07-american-glp-1-usage-hits-record-high",{"id":170,"title":149,"source":171,"logo":18,"time":60},1200244,"https:\u002F\u002Fwww.nytimes.com\u002F2026\u002F07\u002F07\u002Fwell\u002Famericans-taking-weight-loss-drugs.html",{"id":173,"title":137,"source":174,"logo":25,"time":60},1200266,"https:\u002F\u002Fuk.news.yahoo.com\u002Fnumber-americans-taking-glp-1s-184632990.html",{"id":176,"title":71,"source":177,"logo":12,"time":60},1200288,"https:\u002F\u002Fwtam.iheart.com\u002Fcontent\u002F2026-07-07-american-glp-1-usage-hits-record-high",{"id":179,"title":180,"source":181,"logo":14,"time":60},1200263,"GLP-1 Weight-Loss Drug Use Nearly Quadruples In The US Since 2024 As Obesity Rate Continues To Decline","https:\u002F\u002Fwww.healthandme.com\u002Fhealth-news\u002Fglp-1-weight-loss-drug-use-nearly-quadruples-in-the-us-since-2024-as-obesity-rate-continues-to-decline-article-154974553",{"id":183,"title":71,"source":184,"logo":12,"time":60},1200285,"https:\u002F\u002Fkfyr.iheart.com\u002Fcontent\u002F2026-07-07-american-glp-1-usage-hits-record-high",{"id":186,"title":187,"source":188,"logo":11,"time":60},1200264,"Record number of Americans taking weight-loss drugs","https:\u002F\u002Fsjvsun.com\u002Fu-s\u002Frecord-number-of-americans-taking-weight-loss-drugs",{"id":190,"title":71,"source":191,"logo":12,"time":60},1200286,"https:\u002F\u002Fkogo.iheart.com\u002Fcontent\u002F2026-07-07-american-glp-1-usage-hits-record-high",{"id":193,"title":194,"source":195,"logo":5,"time":60},1200261,"Roughly one in eight American adults is now on a GLP-1 drug like Ozempic — a class that grew out of a hormone one Bronx doctor found in Gila monster venom, then patented himself after his own employer passed on it","https:\u002F\u002Fsiliconcanals.com\u002Fj-v-roughly-one-in-eight-american-adults-is-now-on-a-glp-1-drug-like-ozempic-a-class-that-grew-out-of-a-hormone-one-bronx-doctor-found-in-gila-monster-venom-then-patented-himself-after-his",{"id":197,"title":71,"source":198,"logo":12,"time":60},1200283,"https:\u002F\u002Fkfab.iheart.com\u002Fcontent\u002F2026-07-07-american-glp-1-usage-hits-record-high",{"id":200,"title":71,"source":201,"logo":26,"time":60},1200262,"https:\u002F\u002Fwghn.com\u002F2026\u002F07\u002F08\u002Famerican-glp-1-usage-hits-record-high",{"id":203,"title":71,"source":204,"logo":12,"time":60},1200284,"https:\u002F\u002Fklvi.iheart.com\u002Fcontent\u002F2026-07-07-american-glp-1-usage-hits-record-high",{"id":206,"title":71,"source":207,"logo":12,"time":60},1200281,"https:\u002F\u002Fkfyi.iheart.com\u002Fcontent\u002F2026-07-07-american-glp-1-usage-hits-record-high",{"id":209,"title":210,"source":211,"logo":17,"time":60},1200260,"Beyond willpower: The new era of weight loss in Malaysia","https:\u002F\u002Fwww.msn.com\u002Fen-my\u002Fnews\u002Fother\u002Fbeyond-willpower-the-new-era-of-weight-loss-in-malaysia\u002Far-AA276o1y?cvid=6a48d34410344b349eae524f06ba9904&ocid=hpmsn",{"id":213,"title":71,"source":214,"logo":12,"time":60},1200282,"https:\u002F\u002F700wlw.iheart.com\u002Fcontent\u002F2026-07-07-american-glp-1-usage-hits-record-high",{"id":216,"title":71,"source":217,"logo":12,"time":60},1200280,"https:\u002F\u002F1150wima.iheart.com\u002Fcontent\u002F2026-07-07-american-glp-1-usage-hits-record-high","#824579ff","#8245794d",1783672307258]